[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Medical University of Bialystok\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":371},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,51,81,109,134,171,196,220,246,275,295,321,345],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100633645","breathwork-and-stress-investigating-the-mechanisms-of-action-and-effectiveness-of-breathing-interventions-in-modulating-the-psychophysiological-response-to-acute-stress-test-100633645",false,"NCT07529379","Breathwork and Stress: Investigating the Mechanisms of Action and Effectiveness of Breathing Interventions in Modulating the Psychophysiological Response to Acute Stress Test","Inclusion Criteria:\n\n* Healthy adults\n* Aged 18 to 60 years\n* Willingness to participate in all study phases, including preparation and laboratory session.\n* Professionally active individuals or university students.\n\nExclusion Criteria:\n\n* Severe chronic diseases, including metabolic disorders (e.g., diabetes) and mental disorders.\n* Cardiac arrhythmia, history of heart attacks, strokes, or heart surgery.\n* Regular use of medications such as anxiolytics or beta-blockers (excluding hormonal contraception)\n* Pregnancy.\n* Current participation in other scientific experiments.\n* Significant previous experience with breathing techniques or current independent breathwork\u002Fmeditation practice (defined as regular practice for more than 7 days in total within the last 12 months).\n* Professional sports practice.\n* Raynaud's disease\n* Inability to abstain from alcohol, caffeine, and nicotine for the required periods before the experiment",true,"ALL","18 Years","60 Years",{"count":20,"type":21},120,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study investigates whether the psychophysiological benefits of breathing exercises are driven by a specific physiological rhythm (6 breaths per minute) or by the general psychological experience of performing a structured, mindful activity. Researchers aim to determine if \"coherent breathing\", which is hypothesized to synchronize heart and respiratory rhythms, offers unique physiological protection against stress compared to breathing at a natural pace or simple resting. The main questions it aims to answer are:\n\n* Does slow, steady breathing at 6 breaths per minute lower physical stress markers (like heart rate variability and cortisol) better than faster, but structured breathing or just sitting still?\n* Is the calming effect caused by the specific breathing rhythm or simply by performing a structured, relaxing activity?\n\nResearchers will compare three groups to see if the specific rhythm of \"coherent breathing\" offers unique benefits:\n\n1. Group (Interventional): Coherent Breathing: Slow breathing at 6 breaths per minute.\n2. Group (Sham Breathing): Regular breathing at 15 breaths per minute (matching a natural pace).\n3. Spontaneous Breathing (Control Group): Natural, unguided breathing.\n\nParticipants will:\n\n* Complete a one-day preparation phase to become familiar with the breathing technique.\n* Visit the research center for one experimental session.\n* Perform their assigned breathing method before and after a stress test.\n* Take the Maastricht Acute Stress Test (MAST), which involves putting a hand in cold water and doing mental math.\n* Provide saliva samples and have their heart rate variability, and mood measured multiple times.",[27,28,29,30],"Healthy Adult Participants","Acute Stress Reaction","Stress Biomarkers","Healthy",[32,33,34,35,36,37],"Breathwork","Coherent Breathing","Resonance Breathing","Heart Rate Variability","Maastricht Acute Stress Test (MAST)","Cortisol","RECRUITING","2026-04-16",{"date":41,"type":42},"2026-04-21","ACTUAL",{"date":44,"type":21},"2026-04",{"date":46,"type":21},"2026-11",{"name":48,"class":49},"Medical University of Bialystok","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":68,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":50},"100411213","the-bialystok-bariatric-surgery-study-100411213","NCT04634591","The Bialystok Bariatric Surgery Study","BBSS","Inclusion Criteria:\n\n* BMI ≥ 40 kg\u002Fm2, or BMI ≥ 35 and at least one or more obesity-related co-morbidities such as type 2 diabetes (T2D), hypertension, sleep apnea and other respiratory disorders, non-alcoholic fatty liver disease, osteoarthritis, lipid abnormalities, gastrointestinal disorders, or heart disease.\n* Inability to achieve a healthy weight loss sustained for a period of time with prior weight loss efforts\n* Patient consent for participation in research project\n* Willingness in participation in follow-up visits\n\nExclusion Criteria:\n\n* substance abuse,\n* uncontrolled psychiatric illness\n* expected lack of compliance\n* advanced-stage cancer\n\nNon-obese control group:\n\n* BMI \\\u003C30",{"count":59,"type":21},1000,"OBSERVATIONAL","The Bialystok Bariatric Surgery Study (BBSS) is a prospective observational cohort study of patients undergoing bariatric surgery at the First Clinical Department of General and Endocrine Surgery at the Medical University of Bialystok. The BBSS consists of a battery of baseline tests established one month prior to the surgery and repeated at one, three, six, twelve and twenty four-month follow-up clinical visits.",[63,64,65,66,67],"Obesity","Diabetes Mellitus","Metabolic Syndrome","Dyslipidemias","PreDiabetes",[69,70,71,72],"bariatric surgery","diabetes treatment","prediabetes treatment","metabolic surgery","2026-04-09",{"date":75,"type":42},"2026-04-14",{"date":77,"type":42},"2015-09-10",{"date":79,"type":21},"2026-12-31",{"name":48,"class":49},{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":89,"enrollmentInfo":90,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":92,"conditions":93,"keywords":95,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":50},"100633626","changes-in-energy-expenditure-in-response-to-physical-activity-in-healthy-adults-100633626","NCT07529132","Changes in Energy Expenditure in Response to Physical Activity in Healthy Adults","Assessment of Changes in Energy Expanditure in Response to Short-term Physical Activity Measured by Indirect Calorymetry in Healthy Individuals","VITAL","Inclusion Criteria:\n\n* Age 18-30 years\n* Healthy volunteers without chronic diseases\n* Normal resting ECG (regular sinus rhythm, 60-90 bpm)\n* Normal blood pressure according to ESC guidelines\n* Ability and willingness to provide written informed consent\n\nExclusion Criteria:\n\n* Chronic diseases or musculoskeletal injury within the past 6 months\n* Use of tobacco or nicotine products within the past 6 months\n* Blood donation \\>20 mL (except diagnostic) within the past 6 months\n* Use of narcotics, sedatives, or dietary supplements (e.g., creatine) within the past 2 weeks\n* Active infection, fever, or acute illness at the time of study\n* Inability to comply with study instructions (dietary restrictions, abstinence from alcohol\u002Fcaffeine, exercise restrictions)","30 Years",{"count":91,"type":21},20,"This study investigates how short, high-intensity body-weight exercises affect energy use in healthy young adults. The focus is on resting metabolic rate (RMR), total energy expenditure (TEE) and excess post-exercise oxygen consumption (EPOC), measured with a portable indirect calorimetry system (COSMED K5). Participants will be 14 volunteers, seven women and seven men aged 18 to 30 years, recruited from the academic community of the Medical University of Białystok. Each subject will first undergo basic screening, including ECG, blood pressure, and body composition. Measurements will be taken in three phases. In the resting phase, RMR will be recorded after fifteen minutes of quiet sitting. In the exercise phase, participants will perform squats, burpees, or a plank for one minute at maximum effort or sustained position while energy use is continuously monitored. In the recovery phase, EPOC will be measured immediately after exercise to capture short-term changes. Oxygen uptake, ventilation, heart rate, and oxygen saturation will be tracked throughout the session. Environmental conditions such as room temperature and humidity will be standardized, and participants will avoid caffeine, alcohol, and heavy physical activity at least 24 hours before testing. The main aim is to determine whether even one minute of exercise can meaningfully alter EPOC steady state parameters, and to compare the energy cost of different exercise types. The data will be analyzed in relation to anthropometric variables and cardiopulmonary function. Results are expected to improve understanding of short-term energy dynamics and may support more precise recommendations in pulmonary rehabilitation, cardiology, sports medicine, and nutrition. By providing reliable measurements of caloric cost in simple exercises, the study can help design safer and more effective training, rehabilitation, and weight control programs.",[94],"Physical Activities",[96,97,98,99,100,101],"indirect calorimetry, energy expenditure, exercise physiology, pulmonary rehabilitation, body-weight training","resting metabolic rate","excess post-exercise oxygen consumption","plank","squats","burpees","2026-04-07",{"date":75,"type":42},{"date":105,"type":42},"2025-09-01",{"date":107,"type":21},"2026-12",{"name":48,"class":49},{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":118,"conditions":119,"keywords":122,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":128,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":50},"100633627","cardiopulmonary-exercise-testing-in-lung-cancer-patients-before-and-during-oncological-treatment-100633627","NCT07529145","Cardiopulmonary Exercise Testing in Lung Cancer Patients Before and During Oncological Treatment","Assessment of Respiratory Parameters and Physical Performance in Patients With Lung Cancer Qualified for Oncological Treatment Before and During Therapy, With Special Consideration of Cardiovascular Risk: A Cardiopulmonary Exercise Testing Study","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Histologically confirmed lung cancer (any stage)\n* Qualified for standard oncological management (surgery and\u002For systemic therapy)\n* WHO\u002FECOG performance status 0-2\n* Ability to perform cardiopulmonary exercise testing (CPET)\n* Written informed consent\n\nExclusion Criteria:\n\n* Unstable ischemic heart disease\n* Symptomatic cardiac arrhythmias\n* Myocarditis or pericarditis\n* Decompensated heart failure\n* Active deep vein thrombosis\n* Suspected aortic dissection or severe aortic stenosis\n* Poorly controlled asthma\n* Resting oxygen saturation ≤ 85% on room air\n* Clinically relevant treatment-related adverse events above mild intensity (as applicable)\n* Any medical condition that, in the investigator's opinion, precludes safe participation in CPET\n* Withdrawal of informed consent",{"count":117,"type":21},90,"Patients with lung cancer often have reduced physical fitness and coexisting health problems, which may limit their ability to tolerate oncological treatment. Standard resting lung and heart tests do not always reflect real-life physical capacity during everyday activities or physical effort.\n\nThis observational study aims to assess cardiorespiratory fitness in patients with lung cancer before and during standard oncological treatment using cardiopulmonary exercise testing (CPET). CPET is a safe, supervised exercise test that provides objective information on how the heart, lungs, and muscles respond to physical effort.\n\nParticipants with WHO\u002FECOG performance status 0-2 will undergo CPET before treatment initiation and again after the early phase of therapy or surgery. The results may help identify patients with reduced physiological reserve and support individualized monitoring during routine clinical care.",[120,121],"Non-Small Cell Carcinoma of Lung","Small Cell Carcinoma of Lung",[123,124,125,126,127],"lung cancer treatment","cpet","V02peak","ventilatory efficiency","cardiopulmonary exercise testing",{"date":75,"type":42},{"date":130,"type":42},"2026-01-01",{"date":132,"type":21},"2027-09-01",{"name":48,"class":49},{"id":135,"slug":136,"hasResults":11,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":142,"enrollmentInfo":143,"targetDuration":4,"studyType":22,"phases":145,"briefSummary":146,"conditions":147,"keywords":155,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":50},"100631250","coronoary-microcirculation-analysis-network-100631250","NCT07498231","COronoary Microcirculation Analysis NETwork","Assessment of Risk Factors for Coronary Circulatory and Microcirculatory Disorders, Comparison of Invasive and Non-Invasive Diagnostic Methods, and Evaluation of the Impact of Individualized Pharmacotherapy Optimization on Patients' Quality of Life","COMA-NET","Inclusion Criteria:\n\na. Chronic coronary syndrome c. Anginal symptoms \\> CCS class I or angina equivalent d. Myocardial ischemia confirmed by non-invasive testing e. Provision of informed consent to participate in the study\n\nExclusion Criteria:\n\n1. Angiographically significant coronary artery stenosis or FFR \\\u003C 0.8\n2. Renal insufficiency with eGFR \\\u003C 30 ml\u002Fmin\u002F1.73 m²\n3. Left ventricular ejection fraction \\\u003C 40%\n4. Hypertrophic cardiomyopathy\n5. Acute coronary syndrome within \\\u003C 90 days\n6. Percutaneous coronary intervention (PCI) within \\\u003C 90 days\n7. Previous coronary artery bypass grafting (CABG)\n8. Anemia \\\u003C 10 g\u002FdL or thrombocytopenia \\\u003C 100,000\u002FµL\n9. Intraventricular conduction disturbances preventing ST-T segment assessment\n10. Severe concomitant valvular heart disease\n11. Active malignancy\n12. Type 1 diabetes mellitus\n13. Coronary artery anatomical abnormalities precluding assessment using PressureWire X (myocardial bridge causing \\> 50% luminal narrowing of the investigated vessel, severe coronary tortuosity, inability to properly cannulate coronary ostia)\n14. Pregnancy\n15. Heart failure ≥ NYHA class III\n16. Asthma or COPD with severe irreversible airflow obstruction\n17. Atrial fibrillation\n18. Second- or third-degree atrioventricular block without pacemaker implantation (IPG)\n19. Manifest pre-excitation on ECG or history of AVRT episodes without prior ablation of the accessory pathway","75 Years",{"count":144,"type":21},180,[24],"COMA.NET (Coronary Microcirculation Analysis Network) is a prospective, randomized, open-label, parallel-group clinical trial designed to determine whether endotype-guided pharmacotherapy is superior to standard care in improving quality of life in patients with ischemia with non-obstructive coronary arteries. Approximately 180-190 participants with objective ischemia will be randomized to either the control or the intervention group.\n\nPharmacotherapy based on the endotype established during intracoronary assessment will be introduced in the intervention arm of the study. The primary endpoint is the change in the Seattle Angina Questionnaire (SAQ) score from baseline to 3 months. Secondary endpoints include the diagnostic accuracy of transthoracic echocardiographic coronary flow velocity reserve (CFVR), the incidence of adverse events, associations between biomarkers and coronary microvascular dysfunction (CMD), and the identification of risk factors for specific CMD endotypes.\n\nParticipants will undergo invasive functional evaluation of the coronary microcirculation, measurement of echocardiographic CFVR, and analysis of selected circulating biomarkers. The study cohort will be followed up at three and six months and will include reassessment of quality of life (Seattle Angina Questionnaire, EuroQol 5-Dimensions 5-Level questionnaire, 12-item Short Form Health Survey), anxiety (Generalized Anxiety Disorder-7 score), and functional status (6-minute walk test).\n\nThe study began in October 2025. Primary completion is anticipated in October 2027, and the overall study completion date is expected in March 2028.",[148,149,150,151,152,153,154],"Coronary Artery Disease","Microcirculation Resistance","Microcirculation; Biomarkers; Myocardial Ischemia","Microcirculatory Dysfunction","Microcirculatory Status","Echocardiography","Doppler Echocardiography",[156,157,158,159,160,161,162],"coma.net","coma-net","coronary microcirculation","ANOCA","INOCA","angina with non-obstructive coronary arteries","ischemia with non-obstructive coronary arteries","2026-04-02",{"date":165,"type":42},"2026-04-08",{"date":167,"type":42},"2025-10-10",{"date":169,"type":21},"2028-03",{"name":48,"class":49},{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":16,"minAge":179,"maxAge":4,"enrollmentInfo":180,"targetDuration":4,"studyType":22,"phases":182,"briefSummary":183,"conditions":184,"keywords":186,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":50},"100631152","preserflo-microshunt-versus-trabeculectomy-100631152","NCT07496957","Preserflo MicroShunt Versus Trabeculectomy","Preserflo MicroShunt Implantation Versus Trabeculectomy in Managing Open-Angle Glaucoma","PMSvT","Inclusion Criteria:\n\n-\\>21 years of age\n\n* An established diagnosis of: Primary open angle glaucoma, Normal tension glaucoma, Pigment dispersion glaucoma (PDG) or Pseudoexfoliative glaucoma (PEXG)\n* Inadequately controlled on maximum tolerated medical therapy\n* Mean Deviation (MD) \\\u003C\u002F= -3\n* Intraocular pressure of 14-28 mmHg\n* Endothelial Cell Count ≥1000 cells\u002Fmm2\n\nExclusion Criteria:\n\n* An established diagnosis of: Closed-angle glaucoma or Secondary open-angle glaucoma (besides PDG and PEX)\n* Lens status: Aphakic patients or Anterior chamber intraocular lens\n* Previous procedures: Glaucoma shunt\u002Fvalve\u002F surgery or cyclodestructive procedure, Selective laser trabeculoplasty within the past 3 months, Incisional ophthalmic surgery involving the conjunctiva within the past 3 months, Clear corneal cataract or trabecular meshwork surgery conducted within the past 6 months\n* Presence of intraocular silicone oil\n* No light perception vision\n* Current corticosteroid use (ocular or oral)\n* Conjunctival pathologies (e.g., pterygium)\n* Active inflammation (e.g., blepharitis, conjunctivitis, keratitis, uveitis)\n* Vitreous present in the anterior chamber\n* Active iris neovascularization or neovascularization of the iris within 6 months of the surgical date\n* Unwillingness or inability to give consent, accept randomization or return for and participate in scheduled protocol visits","21 Years",{"count":181,"type":21},100,[24],"The goal of this randomized controlled clinical trial is to learn whether two minimally invasive bleb-forming glaucoma implants can effectively treat adult patients with open-angle glaucoma who require surgical lowering of intraocular pressure (IOP). Specifically, the study evaluates whether the PRESERFLO™ MicroShunt is at least as effective as the trabeculectomy in reducing IOP after surgery.\n\nThe main questions it aims to answer are:\n\nDoes the PRESERFLO™ MicroShunt provide IOP reduction at 12 months that is non-inferior to trabeculectomy? How do these two surgeries compare over 12 months with respect to medication reduction, need for additional glaucoma procedures, complications, and preservation of visual function and ocular structures?\n\nParticipants will:\n\nBe randomly assigned (1:1) to receive either the trabeculectomy or the PRESERFLO™ MicroShunt during a single glaucoma surgery.\n\nAttend scheduled follow-up visits over 12 months for eye-pressure measurements, vision testing, visual-field testing, OCT imaging, endothelial-cell counts, and safety assessments.\n\nReceive standard postoperative care and report any complications or additional treatments during the study period.",[185],"GLAUCOMA 1, OPEN ANGLE, D (Disorder)",[187],"open angle glaucoma","2026-03-24",{"date":190,"type":42},"2026-03-27",{"date":192,"type":42},"2026-03-01",{"date":194,"type":21},"2028-12-01",{"name":48,"class":49},{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":16,"minAge":179,"maxAge":203,"enrollmentInfo":204,"targetDuration":4,"studyType":22,"phases":205,"briefSummary":206,"conditions":207,"keywords":209,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":217,"leadSponsor":219,"locationsCount":50},"100584572","vivinex-impress-xy1-em-vs-rayone-emv-100584572","NCT06891092","Vivinex Impress XY1-EM vs RayOne EMV","Comparison of Quality of Vision After Implantation of Monofocal Depth-enhanced Intraocular Lenses in Patients Undergoing Bilateral Cataract Surgery","Inclusion Criteria:\n\n* age-related bilateral cataract\n* age 21 or older\n* visual acuity \\> 0.05\n* axial length: 22.0 - 26.0 mm\n* normal findings in the medical history and physical examination unless the investigator considers an abnormality to be clinically irrelevant\n* written informed consent prior to surgery\n\nExclusion Criteria:\n\n* active ocular disease (e.g. chronic severe uveitis, proliferative diabetic retinopathy, chronic glaucoma not responsive to medication)\n* relevant other ophthalmic diseases such as pseudoexfoliation syndrome (PEX), intraoperative floppy iris syndrome (IFIS)\n* corneal decompensation or corneal endothelial cell insufficiency\n* previous ocular surgery or trauma\n* persons who are pregnant or nursing (pregnancy test will be taken in women of reproductive age)\n* corneal astigmatism \\> 1 dpt.\n* retinopathies","80 Years",{"count":181,"type":21},[24],"Comparison of the outcomes of bilateral implantation of extended depth of vision (EDOF) intraocular lenses (IOLs): the Rayone EMV and the Vivinex Impress XY1-EM in patients with cataract",[208],"Cataract",[210,211,212],"non-diffractive monofocal IOL","EDOF","cataract","2026-01-15",{"date":215,"type":42},"2026-01-20",{"date":130,"type":42},{"date":218,"type":21},"2028-06-01",{"name":48,"class":49},{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":226,"eligibilityCriteria":227,"healthyVolunteers":11,"sex":16,"minAge":228,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":22,"phases":230,"briefSummary":231,"conditions":232,"keywords":234,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":238,"lastUpdatePostDateStruct":239,"startDateStruct":241,"completionDateStruct":242,"leadSponsor":244,"locationsCount":245},"100617971","istent-inject-versus-goniotomy-with-kahook-dual-blade-in-glauocma-treatment-100617971","NCT07325552","iStent Inject Versus Goniotomy With Kahook Dual Blade in Glauocma Treatment","iStent Inject Versus Goniotomy With Kahook Dual Blade in Patients With Ocular Hypertension and Glaucoma","iSKDB","Inclusion Criteria:\n\n* Only one eye per participant\n* Clinically significant cataract\n* Glaucoma or intraocular hypertension treated with one to four medications and no need for filtering glaucoma surgery at the time of study enrollment.\n* Open chamber angle with Schaffer grading three to four in at least two quadrants\n\nExclusion Criteria:\n\n* Previous glaucoma surgery, including cyclodestructive procedures.\n* Selective Laser Trabeculoplasty (SLT) within 90 days prior to planned surgery.\n* Exudative age-related macular degeneration, proliferative diabetic retinopathy, clinically significant corneal dystrophy, other eye disease that affect intraocular eye pressure or visual field.\n* Unable to participate and make written consent due to another medical condition.","18 Weeks",{"count":181,"type":21},[24],"The purpose of the study is to investigate the efficacy of cataract surgery in combination with Kahook Dual Blade Glide goniotomy (KDB) or iStent Inject W Trabecular Microbypass Stent (Istent) in eyes with Open-angle glaucoma.",[233],"Open Angle Glaucoma (OAG)",[235,236,237],"glaucoma","iStent inject","Kahook Dual Blade goniotomy","2026-01-07",{"date":240,"type":42},"2026-01-08",{"date":130,"type":42},{"date":243,"type":21},"2028-01-01",{"name":48,"class":49},2,{"id":247,"slug":248,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":250,"acronym":251,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":253,"minAge":17,"maxAge":254,"enrollmentInfo":255,"targetDuration":4,"studyType":22,"phases":257,"briefSummary":258,"conditions":259,"keywords":261,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":267,"startDateStruct":269,"completionDateStruct":271,"leadSponsor":273,"locationsCount":274},"100484041","multicenter-assessment-of-clinical-utility-pet--mr-with-the-use-of-the-radiotracer-68ga-psma-11-in-therapy-planning-personalized-in-patients-with-prostate-cancer-100484041","NCT05582876","Multicenter Assessment of Clinical Utility PET \u002F MR With the Use of the Radiotracer 68Ga-PSMA-11 in Therapy Planning Personalized in Patients With Prostate Cancer","PROSPETMR2021","Inclusion Criteria:\n\nGroup 1. Patients with diagnosis or high probability of medium and high prostate cancer according International Society of Urological Pathology (ISUP) risk for whom radical treatment is planned\n\n* Prostate adenocarcinoma confirmed by biopsy and histopathological examination\n* Results indicating a moderate RGK (Gleason score 7 or cT2b or PSA 10-20 ng \u002F ml) or high (Gleason score\\> 7 or cT2c or PSA\\> 20 ng \u002F ml) risk according to ISUP\n* Creatinine value allowing for safe PET \u002F MR examination with a contrast agent: creatinine less than or equal to 1.5 times the upper limit of normal, creatinine clearance\\> 60 mL \u002F min\n* Age ≥18 years\n* Signing informed consent to participate in the study\n* Pelvic \u002F prostate mpMR examination performed, not earlier than 30 days before inclusion in the study\n\nGroup 2. Patients with RGK after radical treatment, with biochemical recurrence according to EAU criteria, who are scheduled for further treatment and the result of the imaging \u002F molecular examination may affect change of therapeutic decision:\n\n* Prostate adenocarcinoma confirmed by biopsy and histopathological examination\n* After radical treatment\n* In patients after radical prostatectomy: with at least two PSA measurements ≥0.2 ng \u002F ml not earlier than after 6-13 weeks after radical prostatectomy or PSA≥0.1 with PSAdt (PSA doubling time) \\\u003C3 months PSA on at least two consecutive studies in consecutive last 6 months before qualification (last determination within 6 weeks before qualification) Or\n* In patients after radical radiotherapy: biochemical recurrence defined as nadir PSA + 2 ng \u002F ml\n* Age ≥18 years\n* Signing informed consent\n\nExclusion Criteria:\n\n* Presence of metallic foreign bodies \u002F implants \u002F prostheses \u002F stimulators etc. inside the body, the possession of which is a contraindication to the MR 3T examination\n* Claustrophobia\n* Patient size precluding PET \u002F MR examination due to diameter gantry\n* Known contraindications for the use of radiopharmaceuticals or substances auxiliary (e.g. renal failure and allergy to ingredients in the preparation)\n* Treatment for malignant neoplasm not associated with the prostate gland\n* Participating in another clinical trial\n* Lack of informed consent to participate in the study\n* Age \\\u003C18 years","MALE","99 Years",{"count":256,"type":21},366,[24],"The aim of multicentre phase 3 trial is evidence diagnostic value of 68Ga-PSMA-11 (in PET \u002F CT and PET \u002F MR techniques) in patients with high-risk and intermediate prostate cancer before radical treatment and in diagnosed patients biochemical recurrence after radical treatment",[260],"Prostate Cancer",[262,263,264,265],"PET\u002FCT","PET\u002FMR","68Ga-PSMA-11","PSA","2025-05-05",{"date":268,"type":42},"2025-05-08",{"date":270,"type":42},"2023-01-10",{"date":272,"type":21},"2026-03-31",{"name":48,"class":49},7,{"id":276,"slug":277,"hasResults":11,"nctId":278,"briefTitle":279,"officialTitle":279,"acronym":280,"eligibilityCriteria":281,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":254,"enrollmentInfo":282,"targetDuration":4,"studyType":22,"phases":284,"briefSummary":286,"conditions":287,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":266,"lastUpdatePostDateStruct":289,"startDateStruct":290,"completionDateStruct":292,"leadSponsor":294,"locationsCount":50},"100475140","phase-3-safety-outcomes-post-kidney-biopsy---randomized-clinical-evaluation-of-efficacy-of-desmopressin-100475140","NCT05467033","Safety Outcomes Post Kidney Biopsy - Randomized Clinical Evaluation of Efficacy of Desmopressin","STOP-BLEED","Inclusion Criteria:\n\n1. ≥ 18 years old\n2. Ability to provide Informed Consent\n3. Qualification by nephrologist to kidney biopsy in accordance to current standards\n4. Initial haemoglobin concentration \\> 8g\u002Fdl and PLT count \\>100 x103\u002FμL\n5. Normal range of APTT and INR\n6. Blood pressure control defined as SBP\\\u003C160 mmHg\n7. Permitted antiplatelet\u002Fantithrombotic drugs: acetylsalicylic acid and heparin\n8. No inflammation at the point of biopsy needle insertion\n\nExclusion Criteria:\n\n1. Initial sodium concentration \\\u003C130mmol\u002Fl\n2. Pregnancy and breastfeeding\n3. Anaphylactic shock after desmopressin administration (medical history)\n4. Necessity of administration other anti-platelet \u002F anti thrombotic drugs other than acetylsalicylic acid, non-fractionated heparin or low molecular weight heparin\n5. Decompensated Heart failure\n6. Von Willebrand disease (VWD) type II B\n7. As per Investigator opinion a medical situation which may lead to increased intracranial pressure (ICP)\n8. Hydronephrosis of the biopsied kidney\n9. Usage of any prohibited drug before screening :\n\n   * ASA in dosage \\> 75mg per day\n   * Vitamin K antagonist (VKA)\n   * Direct oral anticoagulants (DOAC)\n   * Low-molecular-weight heparin (LMWH)\n   * Unfractionated heparin (UFH)\n   * Except situation when dosage of listed above drugs will be adjusted in accordance to protocol",{"count":283,"type":21},424,[285],"PHASE3","It is a randomized, multicenter, double-blind, placebo controlled, interventional clinical trial that will be conducted in Poland, in about 6 Hospital Nephrology Departments to evaluate the safety and effectiveness of desmopressin on the prevention of bleeding after percutaneous needle kidney biopsy in patients with rare and ultrarare glomerulonephritis.",[288],"Kidney Biopsy",{"date":268,"type":42},{"date":291,"type":42},"2022-09-01",{"date":293,"type":21},"2026-08-31",{"name":48,"class":49},{"id":296,"slug":297,"hasResults":11,"nctId":298,"briefTitle":299,"officialTitle":300,"acronym":301,"eligibilityCriteria":302,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":303,"enrollmentInfo":304,"targetDuration":4,"studyType":22,"phases":305,"briefSummary":306,"conditions":307,"keywords":309,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":315,"startDateStruct":317,"completionDateStruct":318,"leadSponsor":320,"locationsCount":50},"100465449","genetics-of-the-acute-response-to-oral-semaglutide-100465449","NCT05340868","Genetics of the Acute Response to Oral Semaglutide","Genetics of the Acute Response to Oral Semaglutide (GAROS)","GAROS","Inclusion Criteria:\n\n* Informed consent was given before any study-related action on the subject.\n* Age: 18-65 years old\n* Body mass index (BMI) \\>30 kg\u002Fm2 or \\>27 kg\u002Fm2 when accompanied by prediabetes, diagnosed according to the criteria of the American Diabetes Association\n\nExclusion Criteria:\n\n* Patients diagnosed with a serious chronic disease, including:\n\n  * Ischemic heart disease\n  * Heart failure (NYHA class III-IV)\n  * Severe renal insufficiency (eGFR \\\u003C30 ml\u002Fmin)\n  * Severe liver diseases\n  * Inflammatory bowel disease\n  * Diabetic gastroparesis\n  * Cancer - currently or in the last five years prior to screening\n  * Chronic obstructive pulmonary disease\n  * History of mental illness, major depression or other severe mental disorders\n* Use of any medications with clinically-proven significant weight gain or loss effects\n* History of undergoing bariatric surgery or other surgery involving the stomach that could affect the absorption of the study drug (according to the investigator's opinion)\n* History of idiopathic acute pancreatitis\n* A family or personal history of multiple endocrine neoplasia type 2 (MEN2) or medullary thyroid cancer\n* For women - pregnancy, breastfeeding or planning pregnancy.\n* Women of childbearing age who are not using highly effective methods of contraception\n* Known or suspected hypersensitivity to the test product","65 Years",{"count":59,"type":21},[24],"The study aims to investigate the genetic basis of the response to short-term (3 months) orally administered semaglutide treatment, in terms of improving metabolic parameters, including the hormonal response to a standardized meal, and changes in body composition and liver steatosis. In the study, parameters such as fasting and 2-hour glucose during OGTT, HbA1c, body fat mass, body weight, total cholesterol, HDL and LDL, triglycerides, HOMA-IR, Matsuda Index and liver steatosis will be assessed. All the patients will undergo genome-wide genotyping. Moreover, in a subset of participants, muscle and fat biopsies will be performed, before and after the treatment, and liver, muscle and pancreas fat content will be assessed using MRI.",[67,308,63],"Prediabetic State",[310,311,312,313],"pharmacogenetics","semaglutide","prediabetes","obesity","2025-03-21",{"date":316,"type":42},"2025-03-26",{"date":291,"type":42},{"date":319,"type":21},"2025-12-31",{"name":48,"class":49},{"id":322,"slug":323,"hasResults":11,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":327,"eligibilityCriteria":328,"healthyVolunteers":15,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":329,"targetDuration":331,"studyType":60,"phases":4,"briefSummary":332,"conditions":333,"keywords":336,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":314,"lastUpdatePostDateStruct":339,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":50},"100412961","polish-registry-of-diabetes-polred-100412961","NCT04657367","Polish Registry of Diabetes (PolReD)","Polish Registry of Diabetes - PL: Polski Rejestr Diabetologiczny (PolReD)","PolReD","Inclusion Criteria:\n\n* patients with diagnosed diabetes (according to the American Diabetes Association criteria) - diabetes group\n* patients with diagnosed prediabetes (IFG and\u002For IGT) - prediabetes group\n* patients with normoglycemia (NFG and NGT) - normoglycemia group\n* informed consent\n\nExclusion Criteria:\n\n* drug addiction\n* severe psychiatric disorders\n* patients with gestational diabetes mellitus\n* patients unable to give informed consent, legally incompetent or incapable to comply with the study terms and conditions",{"count":330,"type":21},10000,"10 Years","The aim of this project is to create a registry of diabetic patients, containing a detailed clinical profile of each patient, along with omics data, which will be analyzed using artificial intelligence algorithms, and their results will be implemented in the form of new recommendations of care for high-risk patients and those already suffering from diabetes.\n\nThe study will be conducted prospectively. The project participants will be patients with diabetes, patients at high risk of developing diabetes and a control group of normoglycemic patients who will participate in study visits at the Clinical Research Center of the Medical University of Bialystok.",[334,63,67,335],"Diabetes","Dysglycemia",[337,338],"diabetes registry","prediabetes registry",{"date":316,"type":42},{"date":341,"type":42},"2020-02-03",{"date":343,"type":21},"2030-12-31",{"name":48,"class":49},{"id":346,"slug":347,"hasResults":11,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":351,"eligibilityCriteria":352,"healthyVolunteers":15,"sex":353,"minAge":17,"maxAge":354,"enrollmentInfo":355,"targetDuration":4,"studyType":22,"phases":357,"briefSummary":359,"conditions":360,"keywords":4,"overallStatus":362,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":4},"100517064","phase-2-clinical-trials-evaluating-the-effect-of-metformin-treatment-on-function-endometrium-in-women-diagnosed-with-idiopathic-infertility-100517064","NCT06012682","Clinical Trials Evaluating the Effect of Metformin Treatment on Function Endometrium in Women Diagnosed With Idiopathic Infertility","A Randomized, Controlled, Double-blind Study Clinical Trials Evaluating the Effect of Metformin Treatment on Function Endometrium in Women Diagnosed With Idiopathic Infertility","METIN","Inclusion Criteria:\n\n1. Age 18-45\n2. No pregnancy for a minimum of 12 months prior to screening.\n3. Diagnosed with idiopathic infertility.\n4. No use of hormone therapy 30 days before screening.\n5. No use of any methods of contraception 30 days before screening and during the examination.\n6. BMI between 18.5 - 30 kg\u002Fm2.\n\nExclusion Criteria:\n\n1. Positive pregnancy test result.\n2. Patients diagnosed with another factor of infertility.\n3. Patients with type I or II diabetes.\n4. Patients taking metformin or other hypoglycaemic drugs in the last 4 weeks before screening.\n5. Patients with hepatic impairment and abnormal liver function tests (alanine aminotransferase and\u002For aspartate aminotransferase (above 3x ULN).\n6. Patients with an eGFR less than 45 mL\u002Fmin\u002F1.73m2.\n7. Accompanying chronic diseases with poor prognosis.\n8. Patients with a history of lactic acidosis or other metabolic acidosis.\n9. Patients with a history of congestive heart failure III\u002FIV NYHA degree.\n10. Patients with acute myocardial ischemia.\n11. Patients with sepsis or severe infection.\n12. Diseases which, in the opinion of the investigator, constitute an exclusion criterion and prevent the patient from participating in the study.\n13. Patients with predictable problems with cooperation with the research team.","FEMALE","45 Years",{"count":356,"type":21},200,[358],"PHASE2","Randomized, controlled, double-blind, three-arm clinical trial in which 75 women will be randomized to treatment with metformin, 75 women to treatment with placebo and 50 women to the observation group. The medical intervention will last 24 weeks (6 months). Women with confirmed idiopathic infertility, in whom infertility factors have been excluded during full diagnostics, will be included in the study",[361],"Infertility, Female","NOT_YET_RECRUITING","2023-08-22",{"date":365,"type":42},"2023-08-25",{"date":367,"type":21},"2023-08-30",{"date":369,"type":21},"2027-09-30",{"name":48,"class":49},""]